April 16 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL PHASE 2 SURVIVAL DATA BEATS LEADING STANDARD IN HR+ BREAST CANCER
BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS MEDIAN OVERALL SURVIVAL IN HR+ MBC PATIENTS
BRIACELL THERAPEUTICS CORP - BRIA-IMT SURVIVAL DATA IN TNBC PATIENTS COMPARABLE TO TRODELVY
BRIACELL THERAPEUTICS CORP - NO BRIA-IMT RELATED DISCONTINUATIONS REPORTED TO DATE
Source text: ID:nGNX1GCq2
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.